Novakand Pharma AB
3EE0
Company Profile
Business description
Novakand Pharma AB is developing a new class of innovative drugs focusing on inflammatory diseases and cancer. The company is developing a new class of small molecule drugs that control disease promoting immune cells with precision, by targeting the fractalkine axis.
Contact
Nanna Svarts vag 4
Solna171 65
SWET: +46 850126080
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5
Stocks News & Analysis
stocks
Market too pessimistic about unloved ASX health care share
Our analysts believe a long-term margin recovery is underway.
stocks
Two overvalued ASX shares to avoid
Both shares trade at a significant premium to our fair value.
stocks
Materially undervalued ASX tech share
Long reinvestment runway supports our thesis on ASX technology company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,889.80 | 16.00 | -0.18% |
| CAC 40 | 8,025.80 | 66.13 | 0.83% |
| DAX 40 | 23,464.63 | 225.45 | 0.97% |
| Dow JONES (US) | 47,112.45 | 664.18 | 1.43% |
| FTSE 100 | 9,609.53 | 74.62 | 0.78% |
| HKSE | 26,051.75 | 157.20 | 0.61% |
| NASDAQ | 23,025.59 | 153.59 | 0.67% |
| Nikkei 225 | 49,503.74 | 844.22 | 1.73% |
| NZX 50 Index | 13,578.02 | 97.59 | 0.72% |
| S&P 500 | 6,765.88 | 60.76 | 0.91% |
| S&P/ASX 200 | 8,599.10 | 16.90 | -0.20% |
| SSE Composite Index | 3,867.80 | 2.22 | -0.06% |